A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma
- PMID: 12820450
A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma
Abstract
The therapeutic results of allogeneic bone marrow transplantation (BMT), following a conditioning regimen of total body irradiation and busulphan and melphalan administration, were evaluated in 20 pediatric patients with high-risk leukemia or lymphoma. Twelve patients received BMT from HLA-matched related (MR) donors while eight received transplants from mismatched related or unrelated (MisR/UR) donors. The post-BMT five-year survival rates were much better for patients in the MR donor group (p = 0.0008). The outcomes of patients in the MisR/UR donor group were significantly worse. This was not due to disease recurrence, but to a high incidence of fatal post-transplant infections (p = 0.004). Nine out of twelve patients who received transplants from MR donors have remained in complete remission for a median of 57 (range 27-78) months. These results suggest that this conditioning regimen has a significant anti-neoplastic benefit useful for the preparation of pediatric patients receiving transplants from MR donors; however, refinement is essential before it can be used in patients receiving transplants from MisR/UR donors.
Similar articles
-
Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.Bone Marrow Transplant. 1998 Jul;22(1):21-6. doi: 10.1038/sj.bmt.1701276. Bone Marrow Transplant. 1998. PMID: 9678791
-
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.Pediatr Blood Cancer. 2014 Apr;61(4):712-6. doi: 10.1002/pbc.24922. Epub 2013 Dec 30. Pediatr Blood Cancer. 2014. PMID: 24376191
-
Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.Bone Marrow Transplant. 1996 Sep;18(3):489-94. Bone Marrow Transplant. 1996. PMID: 8879607
-
Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).Semin Oncol. 1993 Aug;20(4 Suppl 4):33-8; quiz 39. Semin Oncol. 1993. PMID: 8342074 Review.
-
High-dose etoposide in allogeneic stem cell transplantation.Cancer Chemother Pharmacol. 2012 Dec;70(6):765-82. doi: 10.1007/s00280-012-1990-z. Epub 2012 Oct 6. Cancer Chemother Pharmacol. 2012. PMID: 23053272 Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials